News|Articles|November 16, 2026

M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics

Listen
0:00 / 0:00

Key Takeaways

  • Johnson & Johnson’s $2.2B upfront Ollin deal includes up to ~$1.125B milestones and a separate Blackstone agreement providing $750M to fund Phase III OLN324 in exchange for royalties and milestones.
  • Eli Lilly’s up to $1.5B Calytrix acquisition centers on a biparatopic antibody targeting mutant calreticulin–driven essential thrombocythemia and myelofibrosis, aiming for disease modification and early-intervention feasibility.
SHOW MORE

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

A wave of new transactions this week is funneling capital and deal-making activity into some of biopharma’s most closely watched disease areas, from retinal disease and blood cancers to Alzheimer’s and next-generation gene delivery.

Johnson & Johnson acquires Ollin Biosciences

Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences, Inc. for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately $1.125 billion.1 Johnson & Johnson is also set to enter into a separate development funding agreement with Blackstone Life Sciences, under which Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase III development of OLN324, contingent upon the acquisition’s close.

In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments, as well as single-digit royalties. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.

Eli Lilly agrees to acquire Calytrix Bio

Calytrix Bio, Inc. announced a definitive agreement for Eli Lilly and Company to acquire the company, with Calytrix shareholders eligible to receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments tied to the achievement of certain clinical and regulatory milestones.2

Calytrix’s lead asset is an investigational biparatopic antibody targeting mutant calreticulin-driven essential thrombocythemia and myelofibrosis.2 It is designed to deliver disease-modifying pan-mutant activity, with a safety and convenience profile intended to support early intervention and long-term treatment.

“Calytrix was founded on the belief that patients with myeloproliferative neoplasms deserve therapies that do more than manage symptoms,” says Brad Prosek, president and chief executive officer of Calytrix Bio. “From the beginning, our goal has been to alter the disease course in mutant calreticulin-driven essential thrombocythemia and myelofibrosis. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum.”

AmyriAD Therapeutics acquires AD04 Alzheimer’s program

AmyriAD Therapeutics B.V. has acquired the AD04 Alzheimer’s disease program and related assets from ADvantage Therapeutics, Inc., acquiring worldwide rights to AD04, including its associated intellectual property, clinical data and regulatory assets.3

The acquisition adds a Phase IIB-ready program targeting neuroinflammation in mild Alzheimer’s disease, complementing AmyriAD’s lead program, Ismidenon, in moderate Alzheimer’s. AD04 is an investigational drug administered subcutaneously, with a mechanism of action initiated by peripheral inflammation that results in inflammation resolution in the brain and the elimination of waste, including lipid microdroplets.3

AmyriAD intends to advance AD04 into Phase IIB development in mild Alzheimer’s disease to prospectively evaluate its safety and efficacy, and members of ADvantage’s clinical and scientific team is set to continue to support AD04 in advisory roles, providing continuity and program expertise as AmyriAD advances development.3

Seawolf Therapeutics signs collaboration with Sanofi

Seawolf Therapeutics has entered a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications, for up to $1.2 billion in research, development and commercial milestones, plus tiered royalties on sales of any resulting products.4

The collaboration centers on Seawolf’s proprietary, redosable lipid nanoparticle-based DNA delivery system, Trident (Targeted RNA-Induced DNA Expression via Nuclear Translocation). Trident is designed to match the potency, redosability, safety, and scalability of RNA-based lipid nanoparticle therapies while overcoming their short-lived expression by delivering DNA-based payloads.4

“Seawolf is charting a new course in patient care through LNP-based DNA medicines,” says Elizabeth Alcamo, Ph.D., president and chief executive officer. “With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”

Sources

  1. Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology Johnson & Johnson November 16, 2026, https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-ollin-biosciences-and-late-stage-bispecific-antibody-with-best-in-class-potential-in-ophthalmology
  2. Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis Calytrix November 16, 2026, https://www.prnewswire.com/news-releases/calytrix-bio-enters-an-agreement-to-be-acquired-by-lilly-to-advance-outcomes-for-patients-living-with-essential-thrombocythemia-and-myelofibrosis-302940325.html
  3. AmyriAD Therapeutics Acquires AD04 Alzheimer's Program from ADvantage, Further Expanding Its Clinical-Stage Cognition Pipeline AmyriAD Therapeutics November 16, 2026, https://www.prnewswire.com/news-releases/amyriad-therapeutics-acquires-ad04-alzheimers-program-from-advantage-further-expanding-its-clinical-stage-cognition-pipeline-302940420.html
  4. Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics Seawolf Therapeutics November 16, 2026, https://www.businesswire.com/news/home/20261116723769/en/Seawolf-Therapeutics-Debuts-With-%24100-Million-to-Advance-DNA-Based-Therapeutics

Related to this article

Pharmaceutical Executive Daily
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.